Yoda1 |
Catalog No.GC18233
One-Click Copy Product Info
|
Yoda1 is an effective selective agonist of Piezo1 with an EC50 value of 17.1µM in mice.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 448947-81-7
Sample solution is provided at 25 µL, 10mM.
- Invest Ophth Vis Sci 67.8 (2026):33-33.PMID:42439605
- Front Pharmacol 16 (2025):1592818.
- Bba-Mol Cell Res 1872.7 (2025):120008.PMID:40517844
- Cell Signal (2026):112507.PMID:41881093
- Neurogastroent Motil (2025):e70219.PMID:41313666
- ACS Omega 6.15 (2021):10196-10206.PMID:34056174
- Mater Today Adv 17 (2023):100325.
Yoda1 is an effective selective agonist of Piezo1 with an EC50 value of 17.1µM in mice[1]. Yoda1 acts as a molecular wedge, facilitating the opening of Piezo1 when the membrane is stretched, promoting the force-induced conformational changes, thereby effectively reducing the mechanical activation threshold of the channel[2]. Yoda1 activates the Piezo1 channel, leading to Ca2+ influx and a subsequent increase in intracellular Ca2+ concentration[3]. Yoda1 has been widely used in vaccine research as an adjuvant to enhance T-cell activation[4].
In vitro, Yoda1 (1.5µM) was incubated for 10 minutes, which significantly inhibited EGF-stimulated macropinocytosis in A431 cells and prevented peripheral ruffle formation[5]. Treatment with 10µM Yoda1 for 48 hours induced apoptosis in MDA-MB-231 cells and inhibited cell migration[6]. Pretreatment with 10µM Yoda1 for 20min reduced the expression of Periostin in 3T3 cells and altered the expression pathways related to the fibrosis process[7].
In vivo, Yoda1 administration via intraperitoneal injection at a dose of 5µmol/kg/day for 5 days promoted angiogenesis in the intestinal ischemia/reperfusion injury of mice and alleviated intestinal damage[8]. Intraperitoneal injection of Yoda1 at a dose of 4μg/kg at 1 hour before and 12 hours after lipopolysaccharide (LPS) treatment alleviated LPS-induced cardiac dysfunction and oxidative stress in mice[9].
References:
[1] Syeda R, Xu J, Dubin A E, et al. Chemical activation of the mechanotransduction channel Piezo1[J]. elife, 2015, 4: e07369.
[2] Botello-Smith W M, Jiang W, Zhang H, et al. A mechanism for the activation of the mechanosensitive Piezo1 channel by the small molecule Yoda1[J]. Nature communications, 2019, 10(1): 4503.
[3] Qiao M, Penttinen R, Coli A, et al. Piezo1 Channel Activators Yoda1 and Yoda2 in the Context of Red Blood Cells[J]. Biomolecules, 2025, 15(8): 1110.
[4] Goon S, Shiu Chen Liu C, Ghosh Dastidar U, et al. Exploring the structural attributes of Yoda1 for the development of new-generation Piezo1 agonist Yaddle1 as a vaccine adjuvant targeting optimal T cell activation[J]. Journal of Medicinal Chemistry, 2024, 67(10): 8225-8246.
[5] Kuriyama M, Hirose H, Masuda T, et al. Piezo1 activation using Yoda1 inhibits macropinocytosis in A431 human epidermoid carcinoma cells[J]. Scientific reports, 2022, 12(1): 6322.
[6] Lin C Y, Song X, Ke Y, et al. Yoda1 enhanced low-magnitude high-frequency vibration on osteocytes in regulation of MDA-MB-231 breast cancer cell migration[J]. Cancers, 2022, 14(14): 3395.
[7] Alam P, Stiens S M, Bowles H J, et al. Yoda1 inhibits TGFβ-induced cardiac fibroblast activation via a BRD4-dependent pathway[J]. Cells, 2025, 14(13): 1028.
[8] Wang C, Luo S, Yan Y, et al. Endothelial Piezo1 stimulates angiogenesis to offer protection against intestinal ischemia–reperfusion injury in mice[J]. Molecular Medicine, 2025, 31(1): 147.
[9] Yang Y, Tian Q, Qiu F, et al. Yoda1/Piezo1 alleviates lipopolysaccharide-induced cardiac injury via AMPK-mediated mitophagy[J]. Cardiovascular Toxicology, 2025, 25(10): 1604-1615.
| Cell experiment [1]: | |
|
Cell lines |
MDA-MB-231 cells |
|
Preparation Method |
MDA-MB-231 cells were cultured in MLO-Y4 medium supplemented with 2.5% calf serum, 2.5% fetal bovine serum, and 1% penicillin streptomycin at 37°C in an incubator with 5% CO2. Cells were seeded in a 96-well plate at a density of 1.5×105 cells/well for 24h, with three replicates for each treatment. Cells were treated with different concentrations of Yoda1 (0, 1, 2, 5, and 10μM). After 48h of treatment, the cell viability was determined. |
|
Reaction Conditions |
0, 1, 2, 5, and 10μM; 48h |
|
Applications |
Yoda1 treatment inhibited the cell viability of MDA-MB-231 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6 J mice |
|
Preparation Method |
Male C57BL/6 J mice (8 weeks old) were maintained in a controlled environment at 21±1°C and 60% relative humidity under a 12h light/dark cycle, and were given free access to food and water. Mice were fasted for 12h before surgery, with water provided ad libitum. Following surgical site preparation, the mice were rendered unconscious through inhalation of 2% isoflurane. A 1-2cm incision was made along the abdominal midline, and then the abdominal layers were sequentially separated. The first-order branch of the superior mesenteric artery was isolated using blunt dissection techniques. Mesenteric ischemia was induced by clamping the ileal vessels with a microvascular clamp, and successful induction was verified by observing the resultant pallor of the ileum. After 30min of ischemia, the clamp was taken away, and the abdominal wound was sutured. The mice were euthanized at 48 and 72h post-reperfusion for further analysis. For Yoda1 treatment, a 50mM stock solution was prepared by dissolving Yoda1 in dimethyl sulfoxide (DMSO). For experimental use, the saline was used to dilute the stock solution to achieve a final concentration of 5µmol/kg. Mice were continuously injected with Yoda1 (5µmol/kg/day) intraperitoneally for 5 days one week before surgery. |
|
Dosage form |
5µmol/kg/day; 5 days; i.p. |
|
Applications |
Yoda1 treatment promoted angiogenesis in the intestinal ischemia/reperfusion injury of mice and alleviated intestinal damage. |
References: [1] Lin C Y, Song X, Ke Y, et al. Yoda1 enhanced low-magnitude high-frequency vibration on osteocytes in regulation of MDA-MB-231 breast cancer cell migration[J]. Cancers, 2022, 14(14): 3395. [2] Yang Y, Tian Q, Qiu F, et al. Yoda1/Piezo1 alleviates lipopolysaccharide-induced cardiac injury via AMPK-mediated mitophagy[J]. Cardiovascular Toxicology, 2025, 25(10): 1604-1615. | |
| Cas No. | 448947-81-7 | SDF | |
| Chemical Name | 2-[5-[[(2,6-dichlorophenyl)methyl]thio]-1,3,4-thiadiazol-2-yl]-pyrazine | ||
| Canonical SMILES | ClC(C=CC=C1Cl)=C1CSC2=NN=C(C3=CN=CC=N3)S2 | ||
| Formula | C13H8Cl2N4S2 | M.Wt | 355.3 |
| Solubility | DMSO：50mg/mL | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.8145 mL | 14.0726 mL | 28.1452 mL |
| 5 mM | 562.9 μL | 2.8145 mL | 5.629 mL |
| 10 mM | 281.5 μL | 1.4073 mL | 2.8145 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
-
Related Biological Data
Mechano-stress upregulates the transcription of POSTN via NF-κB p65 (L) ChIP-qPCR assay was performed with anti-NF-κB p65 using hNPCs treated with PBS, TNF-α, or Yoda1 for 24 h to identify the binding between NF-κB p65 and the POSTN promoter.
Quantitation of Ca2+ influx changes in hNPCs after 5 μM Yoda1(GLPBIO) stimulation (left panel), and representative fluorescence images at indicated time points(right panel). Yoda1 was administrated at 10 s.
Molecular therapy S1525-0016. PMID: 35619555 IF: 11.4545 -
Related Biological Data
The correlation between trans-differentiation and PIEZO1/YAP expression in MSCs. (G) Densitometric analysis of blots showing the values of relevant proteins in MSCs after being treated with Yoda1 and GsMTx4.
PIEZO1 agonist Yoda1 (26.6 μM)(GLPBIO) or antagonist GsMTx4 (2.5 μM) were respectively added in the chambers.
Materials Today Advances 17 (2023): 100325. IF: 9.9176 -
Related Biological Data
FI of intracellular Ca2+ and intracellular Ca2+ levels increased by Yoda1. (a) FIbefore in EC109shRNA‑piezo1 and EC109shRNA‑control cells.
Then, 1 mL of Piezo1 agonist Yoda1 (26.6 μM, Glpbio, USA) was added, and cells were incubated for 10 min.
ACS Omega (2021). PMID: 34056174 IF: 3.51
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)